PORTALBERITA.CO.ID - The widespread use of powerful prescription weight-loss medications in the United Kingdom is now shadowed by concerns regarding sustained results after treatment cessation. An estimated 1.6 million individuals in the UK are currently utilizing these injectable drugs, which have shown remarkable initial efficacy in managing obesity.
What are these medications? As reported by the BBC, the National Health Service (NHS) currently prescribes three main injectable treatments: semaglutide (Wegovy), tirzepatide (Mounjaro), and liraglutide (Saxenda). These drugs are administered via weekly self-injection into common body areas like the thigh or stomach.
How do these drugs work? They function primarily by mimicking the GLP-1 hormone, which signals fullness to the brain, thereby suppressing appetite. Mounjaro offers an added benefit by also influencing metabolic regulation and energy balance.
When do patients see results, and what are the comparative benefits? Patients typically observe weight reduction within weeks of commencing therapy, with clinical trials showing significant outcomes. A study funded by Eli Lilly indicated that Mounjaro led to a 20% weight reduction over 72 weeks, compared to Wegovy’s 14% in a group averaging 113kg.
Why is long-term maintenance a challenge? Medical professionals are cautioning that patients face a high risk of weight regain once they stop the injections because their initial strong food cravings often return. This rebound effect is substantial, according to recent data.
What does the research indicate about stopping treatment? Research published in the British Medical Journal in January 2026 demonstrated that individuals stopping the injections regain weight four times faster than those who complete traditional diet and exercise programs.
Who is advocating for changes in support structures? Because of this rapid rebound, the NHS is being urged to implement regular follow-up appointments and continuous patient support to ensure lasting success.
What are the potential long-term solutions being explored? A study published in Nature Medicine in May 2026, also supported by Eli Lilly, suggested that a daily tablet called orforglipron successfully prevented major weight regain over one year, though researchers noted that lifelong treatment might be necessary.
Where are these drugs currently accessible in the UK? Wegovy injections are available through the NHS in England, Wales, and Scotland for obese adults (BMI of 35+) with associated conditions, but prescriptions are limited to two years.
